CAMBRIDGE，Mass.--（BUSINESS WIRE）--Obsidian TherapeuticsInc。，aclinical-stage biotechnology company pioneering engineered cell and gene therapies，today announced the appointment of Madan Jagasia，M.D.，M.S.，as Chief Executive Officer.A highly experienced clinician and researcher with an extensive industry background in the development of tur-filtean tments for cancer，Dr.Jagasia joins Obsidian as it focues on the advancement and expansion of its clinical program。

Prior to joining Obsidian，Dr.Jagasia was Executive Vice President，Medical Affairs at Iovance Biotherapeutics，Inc.（“Iovance”），where he was responsible for managing national medical affairs，strategic congress planning，advocacy，strategic alliances and external research collaborations.Before Iovance，he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center，Vanderbilt-Ingram Cancer Center，where he co-led Translational Research and Interventional Oncology Research Program at VICC.Dr.Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center.Dr.Jagasia has his M.B.S from the GS Medical College&KEM Hospital， anM.S.and a Master of Management in Health Care from Vanderbilt University。

Obsidian has also named Parameswaran Hari，M.D.，M.S.，as Chief Development Officer.Dr.Hari joins Obsidian from Iovance，where he was Senior Vice President，Clinical Science.He brings decades of experience designing，managing and leading complexcell and gene therapy clinical programs，including TIL therapies.Dr.Hari was formerly the Chief of Hematology and Oncology at the Medical College of Wisconsin and served the American Society of Transplantation and Cellular Therapy（ASTCT）as its secretary。

Additionally，Obsidian announces the appointment of Matthew Norkunas，M.D.，M.B.A.，to its Board of Directors.Dr.Norkunas is an experienced biotechnology executive， currently serving as Chief Financial Officer at Generation Bio.He has previously served as Chief Financial at SomaLogic and has a background in healthcare investing and medicine.Dr.Norkunas began his career as a practicing anesthesiologist.Dr.Norkunas earned a Master of Business Administration Colbisiness， a medical degree from University of Maryland School of Medicine，and a Bachelor of Arts degree from St.Mary’s College of Maryland。

“I am delighted to welcome Drs.Jagasia and Hari to the Obsidian leadership team.Their appointments deepen Obsidian’s clinical expertise and align with the Company’s current focus on clinical development and advancing its lead TIL program，OBX-115，”said Maria Fardis，Ph.D.，Executive Chair of Obsidian’s Board of Directors.“I am appreciative of the critical progress made by the prior leadership in advancing Obsidian through preclinical development and successfully into the clinic。Iam also pleased to announce Dr.Norkunas’appointment to the Board.He brings deep operational experience and strong financial expertise and I look forward to his future contributions to the Board.The Company is well poised for continued advancement in line with our plan.”

About OBX-115

Obsidian’slead investigational cytoTIL15program，OBX-115，infiltrating lymphocyte（TIL）therapy armed with regulated membrane-bound IL15 that has the potential to become a meaningful therapeutic option for patients suffering from metatic melanoma and other solid tumors by leveraging the expectbenefits of mbIL15 and Oidian’s，proetary，differentiated manufacturing process.OBX-115preclinical data have demonstrated enhanced TIL persistence，potency and improved tumor control compared to un-engineered TILs plus IL2.OBX-115also has the potential benefit to patients by removing the need for conitant IL2thery，topistly and costy lerated， limiting the potential eligible patient population for TIL therapy.The Phase I FIH clinical trial for OBX-115 is currently recruiting patients.Information regarding the clinical trial is available at clinicaltrials.gov:NCT 05470283。

About Obsidian Therapeutics

Obsidian Therapeutics，Inc.is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.Obsidian’s proprietory cytoDRiVE®technology provides away to precisely control the timing and level of provingfuncy provides。Obsidian is headquartered in Cambridge，Mass.The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals.For more information，please visitwww.obsidiantx.comand follow us onLinkedInand，and推特。

查看source version on businesswire.com：https://www.businesswire.com/news/home/20230523005283/en/